The Motley Fool fool.com 06 Aug, 2022 11:00 am

Dynavax Technologies (DVAX) Q2 2022 Earnings Call Transcript

DVAX earnings call for the period ending June 30, 2022.

Before we begin, I advise you that we will be making forward-looking statements today based on our current expectations and beliefs, including, but not limited to potential market sizes and market share; market trends; impact of ACIP recommendations and timing of such impact; financial guidance and trends, including revenue, profitability, and sufficiency of current capitalization; timing and results of clinical trial starts and data readouts and potential future uses of CpG 1018 adjuvant.The short summary of the quarter is that we continue to execute well on our core priorities, which has us on track for a second consecutive year of profitability with record revenues expected for HEPLISAV-B and our CpG 1018 adjuvant.Our collaborators have demonstrated that their COVID-19 vaccine platforms adjuvanted with CpG 1018 can provide a combination of high efficacy and immunogenicity with favorable safety and tolerability.In the second quarter, our global portfolio of CpG 1018 adjuvant supply agreements for COVID-19 vaccines generated over $220 million of revenue.

We anticipate full year 2022 revenue for CpG 1018 to be between $550 million and $600 million, which represents the remainder of orders from our partners under our commercial supply agreements.Now beyond COVID-19, we are leveraging our proven CpG 1018 adjuvant to advance our pipeline of new and improved vaccines.

Read full story at fool.com